Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: Characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay

被引:12
作者
Wendelbo, O [1 ]
Bruserud, O
机构
[1] Haukeland Univ Hosp, Dept Med, Div Hematol, Infect Dis Sect, N-5021 Bergen, Norway
[2] Haukeland Univ Hosp, Dept Med, Div Infect Dis, N-5021 Bergen, Norway
[3] Univ Bergen, Bergen, Norway
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2003年 / 12卷 / 05期
关键词
D O I
10.1089/152581603322448231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this methodological study, we describe an assay for analysis of proliferative T cell responses in patients with severe leukopenia. Severe treatment-induced cytopenia is observed in patients with malignant disorders who receive conventional intensive chemotherapy or autologous stem cell transplantation. The quantitative T cell defect can then be characterized by flow cytometric analysis of membrane molecule expression, whereas the functional status of the remaining T cell population is more difficult to evaluate. In the present study, we describe a standardized whole blood assay that requires small sample volumes and can be used for repeated analysis even in severely ill patients. The assay is based on the following strategy: (i) blood samples are diluted with the serum-free medium X-vivo 10(R), (ii) T cells are activated either with monoclonal immunoglobulin E (IgE) anti-CD3 or anti-CD3 plus anti-CD28; (iii) T cell proliferation is assayed by [H-3] thymidine incorporation after 4 days of in vitro culture. These proliferative responses are not affected by the plasma levels of interleukin-2 (IL-2), sIL-2-Ralpha, IL-7 and IL-15, and the kinetics of the response are not altered by the presence of exogenous cytokines. Detectable proliferation is observed for most patients with treatment-induced cytopenia. We conclude that the assay can be used for functional characterization of remaining T lymphocytes in patients with severe T lymphopenia.
引用
收藏
页码:525 / 535
页数:11
相关论文
共 29 条
[21]   GM-CSF in inflammation and autoimmunity [J].
Hamilton, JA .
TRENDS IN IMMUNOLOGY, 2002, 23 (08) :403-408
[22]   LYMPHOCYTE-ACTIVATION .8. APPLICATION OF A WHOLE-BLOOD TEST TO QUANTITATIVE-ANALYSIS OF PHA RESPONSIVE T-CELLS [J].
LUQUETTI, A ;
JANOSSY, G .
JOURNAL OF IMMUNOLOGICAL METHODS, 1976, 10 (01) :7-25
[23]  
Mackall C L, 1999, Oncologist, V4, P370
[24]   AGE, THYMOPOIESIS, AND CD4+ T-LYMPHOCYTE REGENERATION AFTER INTENSIVE CHEMOTHERAPY [J].
MACKALL, CL ;
FLEISHER, TA ;
BROWN, MR ;
ANDRICH, MP ;
CHEN, CC ;
FEUERSTEIN, IM ;
HOROWITZ, ME ;
MAGRATH, IT ;
SHAD, AT ;
STEINBERG, SM ;
WEXLER, LH ;
GRESS, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (03) :143-149
[25]  
MIEDEMA FMR, 1993, J NIH RES, V5, P99
[26]   LOW T-CELL RESPONSIVENESS TO ACTIVATION VIA CD3/TCR IS A PROGNOSTIC MARKER FOR ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) IN HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1)-INFECTED MEN [J].
SCHELLEKENS, PTA ;
ROOS, MTL ;
DEWOLF, F ;
LANGE, JMA ;
MIEDEMA, F .
JOURNAL OF CLINICAL IMMUNOLOGY, 1990, 10 (02) :121-127
[27]   FLT3: Receptor and ligand. Biology and potential clinical application [J].
Shurin, MR ;
Esche, C ;
Lotze, MT .
CYTOKINE & GROWTH FACTOR REVIEWS, 1998, 9 (01) :37-48
[28]  
VANLIER RAW, 1987, J IMMUNOL, V139, P2873
[29]   Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: Studies of systemic IL-7 levels and IL-7 responsiveness of circulating T lymphocytes [J].
Wendelbo, O ;
Glenjen, N ;
Bruserud, O .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2002, 22 (10) :1057-1065